AAP IMPLANTATE AG O.N. news, videos and press releases
For more news please use our advanced search feature.
AAP IMPLANTATE AG O.N. - More news...
AAP IMPLANTATE AG O.N. - More news...
- EQS-Adhoc: aap Implantate AG: Capital increase from authorized capital with exclusion of subscription rights
- EQS-Adhoc: aap proposes to the bondholders of the mandatory convertible bond 2023/2028 an amendment to the bond terms and conditions to enable the bondholders to exercise their conversion rights earlier
- EQS-News: After a mixed 2023 financial year, aap makes a strong start to the 2024 financial year
- More than 100 patients included in the human clinical trial by 31 December 2023; adapted study design meets expectations for accelerated patient recruitment
- EQS-News: aap concludes distribution agreement for LOQTEQ® VA Radius System with leading global spine and orthopedics company
- EQS-Adhoc: Adjustment of the forecast for revenue and EBITDA for FY 2023; implementation of a personnel measure to achieve positive EBITDA and balanced cash flow in the operating trauma business
- EQS-News: Visible acceleration in clinical trial with already more than 60 patients; increase in funding of around EUR 0.4 million underscores innovative strength of silver coating technology
- EQS-Adhoc: aap places mandatory convertible bond 2023/2028 in the amount of EUR 2.5 million
- EQS-Adhoc: aap offers its shareholders a EUR 2.7 million mandatory convertible bond; subscription commitments of around 83% already received; accompanying restructuring measures in preparation
- EQS-News: Hiring of Jochen Rahner as Director Finance, IR and IT to succeed CFO Marek Hahn
- EQS-News: Q2/2023: Revenue growth in all regions (+8 %) and adjusted earnings improvement (EBITDA +21 %)
- EQS-News: Results of aap Implantate AG's Annual General Meeting underpin support for corporate strategy pursued
- EQS-Adhoc: No resolution on certain capital measures at the Annual General Meeting
- EQS-News: Accelerated patient recruitment; adapted study protocol meets expectations for human clinical trial of breakthrough silver antibacterial coating technology
- EQS-News: US and LATAM businesses continue with double-digit growth; Q2 sales increase of +8%; solid growth of +6% in H1/2023
- EQS-News: Proposed capital measures in connection with the convening of the Annual General Meeting: Maintaining freedom of action in a macroeconomic environment characterized by high uncertainties
- EQS-Adhoc: Executive Board proposes in the invitation to the Annual General Meeting various capital measures for resolution
- EQS-News: aap CFO Marek Hahn ends his Management Board activities at the end of the year; contracts of CEO and COO extended until the end of 2025
- EQS-News: Q1/2023: Solid start with slight sales growth (+3 %) and unchanged EBITDA; US and LATAM business grow well into double digits
- EQS-News: Consolidation in FY/2022: Small decline in sales with stable cost base and strong improvement in operating cash flow (+23 %) in challenging environment
- EQS-News: aap Implants Inc. awarded agreement with Premier, Inc. for Small Joint Implants – Upper Extremities, Small Joint Implants – Lower Extremities, Podiatry Products and Accessories
- EQS-News: aap receives US-American clearance (FDA) for polyaxial LOQTEQ® VA Elbow system; launch planned for Q4 2023
- EQS-Adhoc: Result of the capital increase with subscription rights: capital measure fully subscribed; issue of 2.4 million new shares leads to gross issue proceeds of around EUR 3.3 million
- EQS-News: Good start in 2023 after challenging fiscal year 2022
- EQS-Adhoc: aap Implantate AG resolves on capital increase with subscription rights to strengthen its financial base
- EQS-News: Antibacterial silver coating technology: acceleration of human clinical trial through successfully implemented clinical trial protocol changes
- EQS-News: Q3/2022: Again significant growth in the US (+45 %) with sales of EUR 1.0 million; total sales and EBITDA impacted by continued volatile market environment
- EQS-News: Q3/2022: Solid third quarter with slight sales growth in persistently volatile market environment; US business back on track with significant +45 % sales increase
- DGAP-Adhoc: aap launches partnership with strategic investor from the Asian region and resolves on capital increase of around 10 %
- DGAP-News: Q2/2022: Sales of EUR 2.7 million and EBITDA of EUR -0.2 million below expectations in persistently challenging macroeconomic environment; growth expected for second half of 2022